6533b820fe1ef96bd1279b27

RESEARCH PRODUCT

Intravesical mitoxantrone in superficial bladder tumours (Ta-T1)

Carlo PavoneGaspare CorselliMichele Pavone-macalusoVincenzo Serretta

subject

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologyResectionCystitismedicineHumansCarcinoma Transitional CellMitoxantroneChemotherapyUrinary bladderbusiness.industrymedicine.diseaseSurgeryChemical cystitisAdministration IntravesicalTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsOncologyTreatment interruptionChemoprophylaxisMitoxantroneNeoplasm Recurrence Localbusinessmedicine.drug

description

Abstract 36 patients with histologically proven grade G1–G2, Ta-T1 transitional cell carcinoma of the bladder were introduced, after transurethral resection (TUR), into a study of intravesical chemoprophylaxis with mitoxantrone (20 mg diluted in 50 ml). After a mean follow-up of 23 months, 16 (50%) patients showed a superficial recurrence with a mean recurrence rate of 0.56 per year. In 19 patients with recurring tumours the mean recurrence rate decreased from 1.65 to 0.58 per year. 9 patients (25.7%) suffered from a chemical cystitis that in 2 cases (5.7%) required treatment interruption.

yearjournalcountryeditionlanguage
1993-01-01European Journal of Cancer
https://doi.org/10.1016/0959-8049(93)90546-r